Breast Cancer Treatment Decision Making.
DigiStain – The UK’s First Breast Cancer
Risk Profiling Technology
A Digital Solution To Cancer Grading And Prognosis approved by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA), Digistain is a patented risk profiling test for hormone receptor-positive breast cancer patients.
Patented risk profiling test for hormone
receptor-positive breast cancer patients
Results in under 1 hour
Unlike other tests requiring weeks to deliver test results,
Digistain renders results in under an hour informing patients and physicians on the likelihood of breast cancer recurrence within the next 5 to 10 years.
Quick, clear, actionable data
Digistain’s easy-to-read report provides both physician and patient clear actionable information to help determine the best course of treatment and indeed whether cytotoxic therapy in addition to hormone therapy is required.
The MHRA approved Digistain technology is based on 15 years of research and development pioneered by respected cancer research scientists at Imperial College with Professor Chris Phillips of the Biomedical Optics Division and Cancer Research UK (CRUK) with Professor Sir Nicholas Wright of Barts Hospital London, Head of Histopathology at CRUK and ex-president of the Pathological Society of Great Britain.
Delivering radically faster breast cancer treatment decision-making for physicians and patients - reducing actionable treatment decision times from months and weeks to < 1 hour
By deploying a well-established analytical technology for chemical analysis with artificial intelligence to assess patient risk for the first time Digistain accelerates clinical workflow with unparalled efficiency
Trusted by Prominent Cancer Hospitals Across The UK
Clinical Evidence - Equivalent to the Gold Standard
In a double-blinded study with over 848 hormone-positive early stage breast cancer patients DigiStain demonstrated equivalence to the leading NICE approved Next-Generation-Sequencing (NGS) tumour profiling tests
Digistain in Action
Subscribe to leading news and insights
To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.